Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement

B Whitcomb; C Lutman; M Pearl; E Medlin; E Prendergast; K Robison; W Burke

doi:10.1016/j.ygyno.2019.12.013

Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement

Gynecol Oncol. 2020 May;157(2):307-311. doi: 10.1016/j.ygyno.2019.12.013. Epub 2020 Jan 10.

Authors

B Whitcomb¹, C Lutman², M Pearl³, E Medlin⁴, E Prendergast⁵, K Robison⁶, W Burke³

Affiliations

¹ University of Connecticut Health, The Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA. Electronic address: whitcomb@uchc.edu.
² Mission Hope Cancer Center, Santa Maria, CA, USA.
³ Stony Brook Medicine, Stony Brook, NY, USA.
⁴ Lancaster General Health, Penn Medicine, Lancaster, PA, USA.
⁵ Minnesota Oncology, Minneapolis, MN, USA.
⁶ Women & Infants Hospital, Providence, RI, USA.

PMID: 31932107
DOI: 10.1016/j.ygyno.2019.12.013

No abstract available

Keywords: Anti-inflammatory properties of cannabis; Cannabinoids; Chemotherapy induced nausea vomiting; Medical cannabis/medical marijuana; Neuropathy secondary to chemotherapy; Pain management in cancer.

Publication types

Practice Guideline
Review

MeSH terms

Cancer Pain / prevention & control
Cannabinoids / therapeutic use*
Clinical Trials as Topic
Female
Humans
Medical Marijuana / therapeutic use*
Nausea / chemically induced
Nausea / prevention & control
Neoplasms / therapy*
Palliative Care / methods*
Randomized Controlled Trials as Topic
Vomiting / chemically induced
Vomiting / prevention & control

Substances

Cannabinoids
Medical Marijuana